Dashboard
Manage Tickers

VTRS


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

viatris-raises-fy2025-adj-eps-guidance-from-216-230-to-225-235-vs-229-est-raises-fy2025-sales-guidance-from-13500b-14000b-to-13900b-14300b-vs-13928b-est
Viatris Raises FY2025 Adj EPS Guidance fro...
11/06/2025 12:09:32

Viatris (NASDAQ:VTRS) raises FY2025 Adj EPS guidance from $2.16-$2.30 to $2.25-$2.35 vs $2.29 analyst estimate. Raises FY2025 s...

viatris-q3-adj-eps-067-beats-062-estimate-sales-3759b-beat-3609b-estimate
Viatris Q3 Adj. EPS $0.67 Beats $0.62 Esti...
11/06/2025 12:04:38

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.62 by 7.89...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-delivering-high-dividend-yields
Wall Street's Most Accurate Analysts Give ...
10/30/2025 11:09:08

viatris-and-locus-biosciences-enter-research-collaboration-to-develop-precision-antibacterial-therapies-for-ophthalmic-infections
Viatris And Locus Biosciences Enter Resear...
10/28/2025 12:11:42

truist-securities-initiates-coverage-on-viatris-with-buy-rating-announces-price-target-of-15
Truist Securities Initiates Coverage On Vi...
10/15/2025 11:38:44

Truist Securities analyst Srikripa Devarakonda initiates coverage on Viatris (NASDAQ:VTRS) with a Buy rating and announces P...

teva-viatris-on-investor-watch-as-white-house-spares-generic-drugs-from-tariffs
Teva, Viatris On Investor Watch As White H...
10/09/2025 13:31:09

The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply...

mapi-pharma-enrolls-first-patient-into-phase-iii-study-evaluating-cariprazine-once-monthly-injection
Mapi Pharma Enrolls First Patient Into Pha...
09/17/2025 14:05:58

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on developing innovativ...

fda-announces-discontinuation-of-manufacture-of-dymista-nasal-spray-137-mcg-50-mcg-a-registered-trademark-of-meda-pharmaceuticals-inc-a-viatris-company
FDA Announces Discontinuation Of Manufactu...
09/04/2025 15:37:53

https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202236s021lbl.pdf

sp-500-losers-22-stocks-with-negative-returns-over-past-10-years-and-this-ones-getting-the-boot
S&P 500 Losers: 22 Stocks With Negative Re...
08/26/2025 17:02:05

The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to b...

greenlight-capital-announces-q2-2025-trades-new-positions-in-flr-and-vsco-exit-from-vtrs
Greenlight Capital Announces Q2 2025 Trade...
08/16/2025 16:21:08

Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades.

missed-opt-out-deadline-could-cost-investors-millions-in-perrigo-fraud-suit
Missed Opt-Out Deadline Could Cost Investo...
08/13/2025 18:28:17

Perrigo faces a legal battle over whether major investor Sculptor can exit a securities class action years after missing the op...

amphastar-secures-fda-nod-for-iron-sucrose-injection-analysts-eye-major-sales-momentum
Amphastar Secures FDA Nod For Iron Sucrose...
08/12/2025 17:38:58

FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2...

viatris-receives-fda-approval-for-first-generic-venofer-iron-sucrose-injection-with-eligibility-for-180-day-exclusivity
Viatris Receives FDA Approval For First Ge...
08/11/2025 13:30:48

Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic MedicinesApproval Granted with Co...

viatris-affirms-fy2025-adj-eps-guidance-of-216-230-vs-221-est-affirms-fy2025-sales-guidance-of-13500b-14000b-vs-13801b-est
Viatris Affirms FY2025 Adj EPS Guidance of...
08/07/2025 11:06:04

Viatris (NASDAQ:VTRS) affirms FY2025 Adj EPS guidance from $2.16-$2.30 to $2.16-$2.30 vs $2.21 analyst estimate. Affirms FY2025...

viatris-q2-adj-eps-062-beats-055-estimate-sales-3582b-beat-3467b-estimate
Viatris Q2 Adj. EPS $0.62 Beats $0.55 Esti...
08/07/2025 10:59:41

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.55 by 11.9...

Core News & Articles
Earnings Scheduled For August 7, 2025
08/07/2025 08:33:15

viatris-to-present-five-abstracts-from-phase-3-program-evaluating-formulation-of-meloxicam-in-moderate-to-severe-acute-surgical-pain-models-at-painweek-2025-national-conference
Viatris To Present Five Abstracts From Pha...
08/01/2025 14:06:16

Presentations to include efficacy, safety and opioid use reduction data in two different surgery models as well as pharmacokine...

judge-rules-mylan-did-not-infringe-novo-nordisk-patent-in-wegovy-generic-case
Judge Rules Mylan Did Not Infringe Novo No...
07/25/2025 15:28:46

A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, cont...

viatris-hits-snag-in-eye-drug-studyphase-3-plans-under-review
Viatris Hits Snag In Eye Drug Study—Phase ...
07/18/2025 18:17:12

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reasses...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION